skip to content
Primary navigation


Drug - Akynzeo (netupitant and palonosetron)

April 2015

Therapeutic area - Nausea and Vomiting

Approval criteria

  • Patient is receiving moderate to severely emetogenic chemotherapy AND
  • Patient has tried and failed dual therapy with a 5-HT3 antagonist and a substance P/NK1  receptor antagonist

5-HT3 antagonists and substance P/NK1 receptor antagonists include palonosetron, dolasetron, granisetron, ondansetron and aprepitant


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top